Immunome-Derived vaccines- Dr Timothy Messitt EpiVax World Vaccine Congress

Written by on February 11, 2013 in Featured Videos, Prophylactic Vaccines, R&D with 0 Comments

Vaccine design: what’s next?

Last April Dr Timothy Messitt from EpiVax delivered a presentation about the next wave of vaccine design on immune-derived vaccines at the World Vaccine Congress Washington.

See below the key highlights of his presentation:

Immunome-derived are T cell epitope driven vaccines that were developed in order to improve safety (limited potential for autoimmunity) and immunogenicity. Would like to take this into biodefense portfolio.

The focus is on T cell epitopes being able to predict T cell epitopes (Class 1 and 2 MHC binding) using EpiMatrix. The process goes through the following phases:

1. T cell epitope identification:
â– CLUSTIMERS (identifies epitope clusters); potent epitops are promiscuous
â– CONSERVATRIX finds conserved 9mers to be able to protect against as many strains possible
â– Removal of cross-reactive epitopes

2. Expressing epitopes, usually by DNA plasmids followed with peptide boost; optimized whole proteins or VLPs with iso-optimized proteins

3. In vivo evaluation by HLA binding assays

Current vaccines: Burk/Tuly/MP, HIV/TB, Smallpox (VennVax) and others

The company is focusing on an accelerated vaccine approach focusing on biodefense and is planning to integrate all technologies in a web-based toolkit, iVax (currently beta testing it).

Dr Timothy Messitt, Manager, Business Development, EpiVax

Visit our Website:
Read our blog:
Follow us on Twitter: @vaccinenation
Join our Linkedin group:

Tags: ,

About the Author

About the Author: Marketing Manager for Terrapinn's lifescience events #vaccines #syntheticbiology #raredisease #antibodies #biosimilars #stemcells #cellculture #HPAPI .


If you enjoyed this article, subscribe now to receive more just like it.

Subscribe via RSS Feed Connect on Google Plus Join Our LinkedIn Group Connect on YouTube